Navigation Links
Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
Date:4/12/2013

Fairfax, VA (PRWEB) April 12, 2013

As part of its respected in-depth tracking of bio/pharmaceutical industry trends, PharmSource Information Services, Inc. (PharmSource) has just released its annual report analyzing NDA approvals for 2012 and approval trends for the 2006-2012 period.

Geared to bio/pharma contract manufacturers, as well as to bio/pharmaceutical company procurement executives making sourcing decisions, this proprietary 10-page analysis gives critical insight into evolving contract manufacturing trends and developments, and provides an in-depth data-driven analysis, giving a “who’s who” of contract manufacturing organizations (CMOs) that have received NDA approvals and how they stack up. The report includes data and analysis on several leading indicators including:

  •     Approvals by dosage form, including solid dose, injectable and semisolid/liquid. Data for 2012 is compared against the 2006-2011 trends.
  •     Analysis of the distribution of approvals by sponsor type (small, generic, self-sustaining, global), including data on sponsor types for large molecule vs. small molecule approvals. It includes data on the share of approvals type that were outsourced in 2012 for each sponsor, as well as the 2006-2011 average.
  •     The share of NDA approvals that were outsourced over the period from 2006 to 2012, including a comparison of new molecular entities (NMEs) vs. other NDAs.
  •     Data on the top 19 CMOs that received NDA approvals in 2012, and their comparative approval performance during the 2005-2012 period.
  •     2012 NDA approvals with dose CMOs, including 34 products by sponsor, dosage form, approval type, dose contractors and API contractors.

This report is available by subscription to PharmSource’s Strategic Advantage platform, which includes access to all of PharmSource’s intelligence briefings and in-depth syndicated reports, as well as to its global database of contract manufacturers. It also is available as a stand-alone report. For more information, contact PharmSource directly at +1-703-383-4903 / info[at]pharmsource[dot]com.

About PharmSource
PharmSource brings together buyers and sellers of contract services for the development of drugs, medical devices and diagnostics. A trusted provider of global market and business intelligence since 1996, PharmSource publishes reports and databases, and conducts surveys and analyses related to industry contract service activities and trends.

PharmSource contact information:
+1-703-383-4903 Phone (USA, eastern time-zone)
info(at)pharmsource(dot)com
http://www.pharmsource.com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10625157.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
2. Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software
3. Magnetic actuation enables nanoscale thermal analysis
4. Strategic Analysis of the Collagen Peptide Market in the United States
5. Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Psychemedics Corporation Receives New, Additional FDA Clearances for Hair Analysis Drug Testing
8. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
9. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
10. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
11. New wave of technologies possible after ground-breaking analysis tool developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... BIRMINGHAM, United Kingdom (PRWEB) , ... June 28, ... ... and silage storage specialists Bock UK Ltd (Bock) announced a strategic ... the U.K. market. The enzyme technology, OPTIMASH® AD-100, has been shown to help ...
(Date:6/27/2017)... ... ... The recent vote by the American Medication Association to align with the ... and hopefully sheds new light on the way health insurers, governments and the public ... partner of Texas Fertility Center . , “This designation is something we ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... for its patented GX-1 yeast production and fermentation process. The efficiencies created ... rely on micro-organism technologies, most notably the ethanol industry wherein individual production plants ...
(Date:6/26/2017)... ... ... The Workgroup for Electronic Data Interchange (WEDI) , the nation’s leading nonprofit ... and a statutory advisor to the U.S. Department of Health and Human Services (HHS), ... Coordinator for Health Information Technology, will deliver the keynote at its 2017 Summer Forum ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):